BACKGROUND: In 2009, several countries used the ASO3-adjuvanted pandemic A/H1N1 vaccine. We assessed the persistence of antibody and the priming induced by a single paediatric dose of this vaccine in children. METHODS: Children aged 15-120 months vaccinated one year before with the ASO3-adjuvanted monovalent pandemic vaccine were tested for the presence of antibody against 2010-2011 TIV components (A/California/7/2009(H1N1), A/Wisconsin/15/2009 (H3N2 A/Perth/16/2009-like) and B/Brisbane/60/2008) before and 21-28 days after each dose of 2010-2011 TIV. Hemagglutination-inhibition (HAI) assay was used. Children received one or two doses of 2010-2011 TIV at 21-28 days interval in relation with their previous immunization status. RESULTS: The results of 128 children were included in the ATP analysis. Before the 2010-2011 TIV administration, 46% of children showed sero-protection to the A/California/7/2009(H1N1) strain (HAI titre ≥40) with lower rates of sero-protection to the H3N2A/Perth/16/2009 (37%) and B/Brisbane/60/2008 (19%). After the first dose of 2010-2011 TIV, 98%, 75%, and 57% of vaccinees attained a sero-protective titre to A/California/7/2009(H1N1), A/Perth/16/2009(H3N2), and B/Brisbane/60/2008 strain, respectively. The youngest age group showed significantly lower antibody response to the influenza B component compared to the older age groups after the first dose of vaccine. Among vaccinees who received the second dose of TIV, 96% and 87% had a sero-protective titre to H3N2A/Perth/16/2009 and B/Brisbane/60/2008, respectively. The 2010-2011 TIV was well tolerated. CONCLUSIONS: We found substantial persistence of antibody to the A/California/7/2009 strain one year after a single paediatric dose of AS03-adjuvanted pandemic vaccine and a seroprotective level of antibody to this strain in virtually all children who received one year later a single dose of the 2010-2011 TIV. In contrast, two doses of the 2010-2011 TIV were necessary to induce an adequate immune response to the A/Perth/16/2009(H3N2) and B/Brisbane/60/2008 strains in children previously naïve to seasonal vaccine.
BACKGROUND: In 2009, several countries used the ASO3-adjuvanted pandemic A/H1N1 vaccine. We assessed the persistence of antibody and the priming induced by a single paediatric dose of this vaccine in children. METHODS:Children aged 15-120 months vaccinated one year before with the ASO3-adjuvanted monovalent pandemic vaccine were tested for the presence of antibody against 2010-2011 TIV components (A/California/7/2009(H1N1), A/Wisconsin/15/2009 (H3N2 A/Perth/16/2009-like) and B/Brisbane/60/2008) before and 21-28 days after each dose of 2010-2011 TIV. Hemagglutination-inhibition (HAI) assay was used. Children received one or two doses of 2010-2011 TIV at 21-28 days interval in relation with their previous immunization status. RESULTS: The results of 128 children were included in the ATP analysis. Before the 2010-2011 TIV administration, 46% of children showed sero-protection to the A/California/7/2009(H1N1) strain (HAI titre ≥40) with lower rates of sero-protection to the H3N2A/Perth/16/2009 (37%) and B/Brisbane/60/2008 (19%). After the first dose of 2010-2011 TIV, 98%, 75%, and 57% of vaccinees attained a sero-protective titre to A/California/7/2009(H1N1), A/Perth/16/2009(H3N2), and B/Brisbane/60/2008 strain, respectively. The youngest age group showed significantly lower antibody response to the influenza B component compared to the older age groups after the first dose of vaccine. Among vaccinees who received the second dose of TIV, 96% and 87% had a sero-protective titre to H3N2A/Perth/16/2009 and B/Brisbane/60/2008, respectively. The 2010-2011 TIV was well tolerated. CONCLUSIONS: We found substantial persistence of antibody to the A/California/7/2009 strain one year after a single paediatric dose of AS03-adjuvanted pandemic vaccine and a seroprotective level of antibody to this strain in virtually all children who received one year later a single dose of the 2010-2011 TIV. In contrast, two doses of the 2010-2011 TIV were necessary to induce an adequate immune response to the A/Perth/16/2009(H3N2) and B/Brisbane/60/2008 strains in children previously naïve to seasonal vaccine.
Authors: Mark G Thompson; Jessie Clippard; Joshua G Petrie; Michael L Jackson; Huong Q McLean; Manjusha Gaglani; Evelyn C Reis; Brendan Flannery; Arnold S Monto; Lisa Jackson; Edward A Belongia; Kempapura Murthy; Richard K Zimmerman; Swathi Thaker; Alicia M Fry Journal: Pediatr Infect Dis J Date: 2016-03 Impact factor: 2.129
Authors: Rebecca J Hart; Michelle D Stevenson; Michael J Smith; A Scott LaJoie; Keith Cross Journal: JAMA Pediatr Date: 2018-01-02 Impact factor: 16.193
Authors: David Hallengärd; Fok-Moon Lum; Beate M Kümmerer; Aleksei Lulla; Valeria Lulla; Juan García-Arriaza; John K Fazakerley; Pierre Roques; Roger Le Grand; Andres Merits; Lisa F P Ng; Mariano Esteban; Peter Liljeström Journal: J Virol Date: 2014-09-10 Impact factor: 5.103
Authors: Danuta M Skowronski; Marie-Eve Hamelin; Naveed Z Janjua; Gaston De Serres; Jennifer L Gardy; Chantal Rhéaume; Xavier Bouhy; Guy Boivin Journal: PLoS One Date: 2012-06-22 Impact factor: 3.240
Authors: Woolf T Walker; Philip de Whalley; Nick Andrews; Clarissa Oeser; Michelle Casey; Louise Michaelis; Katja Hoschler; Caroline Harrill; Phoebe Moulsdale; Ben Thompson; Claire Jones; Jem Chalk; Simon Kerridge; Tessa M John; Ifeanyichukwu Okike; Shamez Ladhani; Richard Tomlinson; Paul T Heath; Elizabeth Miller; Saul N Faust; Matthew D Snape; Adam Finn; Andrew J Pollard Journal: Clin Infect Dis Date: 2012-01-19 Impact factor: 9.079
Authors: David W Scheifele; Marc Dionne; Brian J Ward; Curtis Cooper; Otto G Vanderkooi; Yan Li; Scott A Halperin Journal: Hum Vaccin Immunother Date: 2013-01 Impact factor: 3.452
Authors: Joanne M Langley; Alfonso Carmona Martinez; Archana Chatterjee; Scott A Halperin; Shelly McNeil; Keith S Reisinger; Naresh Aggarwal; Li-Min Huang; Ching-Tien Peng; José Garcia-Sicilia; Ignacio Salamanca de la Cueva; Fernando Cabañas; Consuelo Treviño-Garza; Miguel Angel Rodríguez-Weber; Manuel de la O; Vijayalakshmi Chandrasekaran; Walthère Dewé; Aixue Liu; Bruce L Innis; Varsha K Jain Journal: J Infect Dis Date: 2013-07-11 Impact factor: 5.226